Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019

BACKGROUND: Broad direct-acting antiviral (DAA) access may reduce hepatitis C virus (HCV) incidence through a “treatment as prevention” (TasP) effect. We assessed changes in primary HCV incidence following DAA access among people living with HIV (PLHIV). METHODS: We used pooled individual-level data...

Descripción completa

Detalles Bibliográficos
Autores principales: van Santen, Daniela K., Sacks-Davis, Rachel, Stewart, Ashleigh, Boyd, Anders, Young, Jim, van der Valk, Marc, Smit, Colette, Rauch, Andri, Braun, Dominique L., Jarrin, Inmaculada, Berenguer, Juan, Lazarus, Jeffrey V., Lacombe, Karine, Requena, Maria-Bernarda, Wittkop, Linda, Leleux, Olivier, Salmon, Dominique, Bonnet, Fabrice, Matthews, Gail, Doyle, Joseph S., Spelman, Tim, Klein, Marina B., Prins, Maria, Asselin, Jason, Stoové, Mark A., Hellard, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816910/
https://www.ncbi.nlm.nih.gov/pubmed/36618902
http://dx.doi.org/10.1016/j.eclinm.2022.101810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816910/
https://www.ncbi.nlm.nih.gov/pubmed/36618902
http://dx.doi.org/10.1016/j.eclinm.2022.101810

Ejemplares similares